Dr. Emil Lou, Intima Bioscience Principal Investigator, Named to 2026 TIME100 Health List Read Press Release Contact A clinical-stage company focused on a next-generation small molecule checkpoint inhibitor CISH IMMUNE CHECKPOINT TARGET THE NEXT GENERATION OF CANCER PLATFORM TECHNOLOGY CISH: a novel immune checkpoint Small molecule checkpoint inhibitor DRUGGING THE UNDRUGGABLE INTIMA BIOSCIENCE CLINICAL TRIAL … Continue reading Home Page